Surf Wiki
Save to docs
general/experimental-drugs-developed-for-schizophrenia

From Surf Wiki (app.surf) — the open knowledge base

Bitopertin

Chemical compound

Chemical compound

Bitopertin (developmental code names RG1678; RO-4917838) is a glycine reuptake inhibitor which was under development by Roche as an adjunct to antipsychotics for the treatment of persistent negative symptoms or suboptimally controlled positive symptoms associated with schizophrenia. Research into this indication has been largely halted as a result of disappointing trial results. As of 2024, it is under development for the management of erythropoietic protoporphyria (EPP).

Bitopertin is a glycine transporter 1 (GlyT1) inhibitor that increases levels of the neurotransmitter glycine by inhibiting its reuptake from the synaptic cleft. Glycine acts as a required co-agonist along with glutamate at N-methyl-D-aspartate (NMDA) receptors.

Erythropoietic protoporphyria

Glycine is an early and crucial substrate in the biosynthesis of haem; inhibiting its transport by blocking GlyT1 reduces its availability for haem biosynthesis and this reduces the downstream accumulation of protoporphyrin IX in people with EPP.

Schizophrenia

Dysfunction of NMDA receptors may play a key role in the pathogenesis of schizophrenia and modulation of glutamatergic signalling via increased concentrations of glycine in the synaptic cleft may help potentiate NMDA receptor function and improve the symptoms of schizophrenia.

In a phase II proof-of-concept study, patients on bitopertin experienced a significant improvement in the change of the Negative Symptom Factor Score from baseline within 8 weeks (from −4.86 in the placebo group to −6.65 in the treatment group, p

In January 2014, Roche reported that bitopertin failed to meet its endpoints in two phase III trials assessing its efficacy in reducing negative symptoms of schizophrenia. Subsequently, in April 2014, Roche announced that it was discontinuing all except one of its phase III trials of bitopertin for schizophrenia.

References

References

  1. (June 2014). "Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study". JAMA Psychiatry.
  2. Medscape. (2014). "Bitopertin Disappoints as Schizophrenia Treatment".
  3. (27 May 2024). "Drug trial allows man with rare sunlight 'allergy' to take first pain-free steps outside".
  4. (1 November 2023). "Bitopertin for Erythropoietic Protoporphyria: A New Paradigm — and New Hope — for a Rare, Devastating Disease". The Hematologist.
  5. [http://euroscan.org.uk/technologies/technology/view/1948 "Bitopertin for schizophrenia"] {{webarchive. link. (30 July 2012 , "EuroScan", 14 August 2012)
  6. Glycine Transporter Type 1 (GLYT1) Inhibitor RG1678: Positive Results of the Proof-of-Concept Study for the Treatment of Negative Symptoms in Schizophrenia, Umbricht D. et al., ACNP 2010
Info: Wikipedia Source

This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.

experimental-drugs-developed-for-schizophrenia glycine-reuptake-inhibitors n-benzoylpiperazines trifluoromethyl-compounds benzosulfones organofluorides
Want to explore this topic further?

Ask Mako anything about Bitopertin — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report